STOCK TITAN

Moderna, Inc. - $MRNA STOCK NEWS

Welcome to our dedicated page for Moderna news (Ticker: $MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Moderna's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Moderna's position in the market.

Rhea-AI Summary

Moderna announced that three abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago. The abstracts include studies on V940 combined with pembrolizumab for the treatment of high-risk melanoma and early-stage non-small-cell lung cancer. A three-year update on a study involving V940 and pembrolizumab in resected melanoma will also be presented. Moderna will host an investor event via webcast on June 3 at 6:15 PM CDT.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.67%
Tags
none
-
Rhea-AI Summary

Moderna, Inc. (MRNA) will be presenting at upcoming investor conferences in May and June 2024. The company will participate in events such as Bernstein's 40th Annual Strategic Decisions Conference, Jefferies Healthcare Conference, and Goldman Sachs 45th Annual Global Healthcare Conference. Investors can access live webcasts and replays of these presentations on Moderna's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.13%
Tags
conferences
-
Rhea-AI Summary

Moderna, Inc. (NASDAQ: MRNA) receives an update from the U.S. FDA regarding the review of its investigational RSV vaccine, mRNA-1345. The FDA will not complete the review by the PDUFA date of May 12, 2024, due to administrative constraints but expects to finish it by the end of May 2024. Moderna remains optimistic about the review and is on track for a CDC Advisory Committee meeting in June 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.39%
Tags
none
Rhea-AI Summary

Moderna reported first quarter revenues of $167 million, with a GAAP net loss of $1.2 billion. The company reaffirmed its 2024 expected product sales of approximately $4 billion. Moderna initiated three new clinical studies for cancer treatment, advanced three new vaccine programs, and provided updates on its COVID-19 and RSV vaccine commercial efforts. Financially, the company saw a decline in revenue due to reduced sales of its COVID-19 vaccine, with cost of sales decreasing by 88%. Research and development expenses decreased by 6% while selling, general, and administrative expenses decreased by 10%. Moderna's net loss was $(1.2) billion, with diluted EPS of $(3.07). The company maintains a cash, cash equivalents, and investments position of $12.2 billion as of March 31, 2024. Looking ahead, Moderna reaffirmed its 2024 revenue expectations, with key milestones in its late-stage pipeline, including respiratory vaccines, next-generation COVID-19 vaccine, and various other vaccine and therapeutics programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.68%
Tags
-
Rhea-AI Summary
Moderna, Inc. (MRNA) will showcase data on its respiratory portfolio and cytomegalovirus research at the ESCMID Global Congress. The company will present nine presentations, including COVID-19 vaccine efficacy, influenza vaccine trials, and respiratory syncytial virus and cytomegalovirus studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
conferences
-
Rhea-AI Summary
Moderna and OpenAI have teamed up to advance mRNA medicine through the integration of generative AI tools. Moderna's collaboration with OpenAI aims to leverage AI's transformative potential in business and healthcare, with successful implementation of ChatGPT Enterprise and other AI capabilities across the organization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
none
Rhea-AI Summary
Moderna, Inc. (MRNA) secures a contract with Brazil's Ministry of Health to supply 12.5 million doses of its mRNA COVID-19 vaccine for the national vaccination campaign. The agreement follows ANVISA's approval of the vaccine for children and adults, emphasizing Moderna's global health commitment. Delivery of doses is expected in Q2 2024, supporting Brazil's fight against COVID-19 and global immunization efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
covid-19
-
Rhea-AI Summary
Moderna, Inc. (MRNA) will report its first quarter 2024 financial results on May 2, 2024. The company will host a live conference call and webcast to provide a corporate update. The webcast will be available on Moderna's website for one year after the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
conferences earnings
-
Rhea-AI Summary
Moderna, Inc. (MRNA) announces positive interim data for mRNA-3927 in treating propionic acidemia, a rare metabolic disorder. The data shows early signs of clinical benefit with infrequent side effects. The ongoing global Phase 1/2 trial demonstrates the therapy's safety and tolerability in participants aged one year and older. mRNA-3927 has been well tolerated with no dose-limiting toxicities observed, reducing the risk of metabolic decompensation events by 70%. The study aims to further evaluate the therapy's efficacy, safety, and pharmacodynamic activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
News
Rhea-AI Summary
CARsgen Therapeutics Holdings (2171.HK) announced its 2023 Annual Results, highlighting NDA and IND approvals, successful clinical trials, collaboration agreements with Huadong Medicine and Moderna, and advancements in CAR T-cell therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
none
Moderna, Inc.

Nasdaq:MRNA

MRNA Rankings

MRNA Stock Data

58.71B
344.86M
9.63%
73.16%
5.6%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About MRNA

moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a